Evidence map›Paper›PMID 28581512›Full record

ArticleNature structural & molecular biology2017

Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.

Jun Lu, Noel Byrne, John Wang, Gerard Bricogne, Frank K Brown, Harry R Chobanian, Steven L Colletti, Jerry Di Salvo, Brande Thomas-Fowlkes, Yan Guo and 24 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature structural & molecular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 194 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Bitopic AJournal of medicinal chemistry · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. G Protein-Coupled Receptor-Ligand Pose and Functional Class Prediction.International journal of molecular sciences · 2024
    Article
  17. Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Review
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 2 institutions in 2 countries.

Jun LuDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Noel ByrneDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
John WangDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Gerard BricogneGlobal Phasing Limited, Cambridge, UK.
Frank K BrownDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Harry R ChobanianDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Steven L CollettiDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Jerry Di SalvoDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Brande Thomas-FowlkesDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Yan GuoDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Dawn L HallDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Jennifer HadixDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Nicholas B HastingsDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Jeffrey D HermesDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Thu HoDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Andrew D HowardDepartment of Cardiometabolic Disease, Merck Research Laboratories, West Point, Pennsylvania, USA.
Hubert JosienDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Maria KornienkoDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Kevin J LumbDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-2778-9956
Michael W MillerDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Sangita B PatelDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Barbara PioDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Christopher W PlummerDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Bradley S SherborneDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Payal ShethDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Sarah SouzaDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Srivanya TummalaDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Clemens VonrheinGlobal Phasing Limited, Cambridge, UK.
Maria WebbDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Samantha J AllenDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Jennifer M JohnstonDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
Adam B WeinglassDepartment of In vitro Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
Sujata SharmaDepartment of Screening and Protein Science, Merck Research Laboratories, West Point, Pennsylvania, USA.
Stephen M SoissonDepartment of Structural Chemistry, Merck Research Laboratories, West Point, Pennsylvania, USA.
United States Military Academy · USGlobal Phasing (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus. Full allosteric agonists (AgoPAMs) of GPR40 bind to a site distinct from partial agonists and can provide additional efficacy. We report the 3.2-Å crystal structure of human GPR40 (hGPR40) in complex with both the partial agonist MK-8666 and an AgoPAM, which exposes a novel lipid-facing AgoPAM-binding pocket outside the transmembrane helical bundle. Comparison with an additional 2.2-Å structure of the hGPR40-MK-8666 binary complex reveals an induced-fit conformational coupling between the partial agonist and AgoPAM binding sites, involving rearrangements of the transmembrane helices 4 and 5 (TM4 and TM5) and transition of the intracellular loop 2 (ICL2) into a short helix. These conformational changes likely prime GPR40 to a more active-like state and explain the binding cooperativity between these ligands.

Indexed as

Allosteric RegulationBinding SitesCrystallography, X-RayHumansModels, MolecularProtein BindingProtein ConformationReceptors, G-Protein-CoupledFFAR1 protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID28581512
OpenAlexW2622916369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.